Market News & Trends
Quotient Sciences & Vasa Therapeutics Announce Dosing of First Subjects With Novel Heart Failure Treatment
VS-041, a novel and potentially life-saving treatment for heart failure, developed by Vasa Therapeutics, a San Diego-based biotechnology company, has reached a major clinical milestone…
Incendia Therapeutics Enrolls First Patient in Phase 1c Clinical Trial of a Novel DDR1 Inhibitor
Incendia Therapeutics, a precision oncology company discovering and developing a novel class of therapies that reprogram the tumor microenvironment (TME), recently announced the first patient…
Belite Bio Announces First Patient Dosed in Phase 2/3 Trial of Tinlarebant for the Treatment of Stargardt Disease
Belite Bio, Inc recently announced that the first patient has been dosed at the Tokyo Medical Center in the Phase 2/3 portion of its DRAGON…
Incannex Healthcare Announces Strategic Financing for up to $60 Million
Incannex Healthcare Inc. recently announced it has entered into an agreement to issue up to $10 million in secured convertible notes to Arena Investors, LP…
Tanvex Appoints Biopharma Industry Veteran as New CEO
Tanvex BioPharma, Inc., the biosimilar-focused biopharmaceutical company and CDMO, recently announced its Board of Directors has appointed Stephen Lam as the company's Chief Executive Officer,…
Cartesian Therapeutics Receives FDA Rare Pediatric Disease Designation for Descartes-08 for the Treatment of Juvenile Dermatomyositis
Cartesian Therapeutics, Inc. recently announced the US FDA has granted Rare Pediatric Disease Designation to Descartes-08 for the treatment of juvenile dermatomyositis (JDM). Descartes-08, Cartesian’s…
Hongene Biotech Corporation & ReciBioPharm Establish a Gene Editing Development Partnership
Hongene Biotech Corporation and ReciBioPharm have announced a strategic collaboration that will enhance gene editing drug manufacturing capabilities. Hongene, renowned for its expertise in the…
GRIN Therapeutics Announces Positive Topline Data from Honeycomb Trial of Radiprodil in GRIN-Related Neurodevelopmental Disorder
GRIN Therapeutics, Inc. recently reported topline results from the its ongoing two-part global Phase 1b open-label trial evaluating the safety, tolerability, pharmacokinetics, and efficacy of…
Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients With Lymphatic Malformations
Protara Therapeutics, Inc. recently announced completion of the first cohort of the Phase 2 STARBORN-1 trial evaluating TARA-002, an investigational cell-based immunopotentiator, for the treatment…
Symbiosis Announces Acquisition of New Facility & Investment in Automated Commercial-Scale GMP Sterile Manufacturing Capability
Symbiosis Pharmaceutical Services Ltd (Symbiosis), a rapidly growing sterile biopharmaceutical Contract Manufacturing Organization (CMO) announces the purchase of new premises in Stirling, Scotland, UK. The…
Serán More Than Doubles Clinical Manufacturing Capacity in Bend, OR
Serán BioScience, LLC, the science-driven drug development partner, recently announced it has completed an expansion to increase the number of process manufacturing suites at its…
ENA Respiratory Announces Extension of US Department of Defense Funding for Novel Prophylactic Antiviral
ENA Respiratory has been awarded an additional $3.13 million contract from the U.S. Department of Defense (DOD). The new funding extends the $8.18 million already…
Voyager Enters License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14
Voyager Therapeutics, Inc. recently announced Novartis AG has agreed to license a novel capsid generated from Voyager’s TRACER capsid discovery platform for use in a…
Vetter's European Clinical Site Successfully Completes First 100 Aseptic Fills
Vetter, a leading global Contract Development and Manufacturing Organization (CDMO), has successfully completed the first 100 clinical batches of liquid and lyophilized vials at its…
Shuttle Pharma Announces Issuance of US Patent for Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease
Shuttle Pharmaceuticals recently announced the issuance of US Patent No. 12,077,515, titled Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease. This patent was…
Lonza Completes Expansion of Microbial Manufacturing Facility in Visp (CH)
Lonza, a global partner to the pharmaceutical, biotech, and nutraceutical markets, recently announced it has completed a planned expansion of the mid-scale microbial manufacturing facility…
Rigel Announces First Patient Enrolled in Phase 1b/2 Trial of REZLIDHIA (olutasidenib) in mIDH1 AML
Rigel Pharmaceuticals, Inc.recently announced the first patient has been enrolled in a Phase 1b/2 triplet therapy trial of decitabine and venetoclax in combination with REZLIDHIA…
Sonoma Biotherapeutics Receives $45-Million Milestone Payment From Regeneron
Sonoma Biotherapeutics, Inc. recently announced it has received a $45-million milestone payment from Regeneron Pharmaceuticals, Inc., under the terms of its active collaboration to discover,…
Recipharm Introduces ReciPredict to Revolutionize Drug Product Development & Manufacturing
Recipharm recently announced the launch of ReciPredict, a cutting-edge platform for Quality by Design (QbD), designed to transform the landscape of drug product development, tech…
Kymanox & SHL Medical Enter Non-Exclusive Strategic Partnership Agreement to Support Delivery of Modern Medicines
Kymanox Corporation and SHL Medical AG recently announced they have signed a non-exclusive strategic partnership agreement. This collaboration establishes a reciprocal preferred partnership between the…
